What a Private Equity Veterinary Practice Buyer Hold Period Means for Your Sale in 2026

Key takeaways

• The PE sponsor behind a buyer matters as much as the headline number. A sponsor three years into a 5-year fund and a sponsor that just closed a fresh fund have fundamentally different exit timelines — and that gap determines how long your rolled equity stays locked up.
• The private equity veterinary practice buyer hold period runs 3 to 7 years in most cases — though the post-2022 rate environment pushed many sponsors well past that window, with billions in aging portfolio value still waiting for an exit.
• The “second bite” is real but not guaranteed. If the platform grows and exits at a favorable valuation, your rolled equity can produce a second check larger than the first. If the platform struggles, the second bite can shrink or disappear.
• Rollover equity is illiquid — you cannot force the PE firm to buy you out. Negotiate a defined liquidity window before you sign, not after.
• Capstone Partners reports 18 pet sector M&A deals YTD in 2026, up from 8 in the prior year period, with financial sponsors expected to accelerate exits through 2026 and 2027 as LP pressure for distributions intensifies.

I sat with a veterinarian over dinner a few months ago who’d received a compelling offer from a well-known PE-backed buyer. The headline number was strong.

The structure was reasonable. But when I asked her one question, she went quiet.

“What do you know about their sponsor’s fund?”

She didn’t know much. And that’s the gap this article closes.

The PE firm that backs a buyer isn’t just a financial detail in the fine print. It’s the clock that governs your rolled equity, the entity that decides when the platform exits, and the institution whose fund lifecycle determines whether your second check arrives in three years or ten. Understanding the private equity veterinary practice buyer hold period — how long a sponsor typically holds before exiting — is the difference between rolling equity with open eyes and signing paperwork you’ll spend a decade regretting.

This is a focused companion to the broader discussion of how private equity prices vet practices. We won’t rehash the valuation math here.

What we will do is explain what a PE sponsor actually is, how fund lifecycles govern exit timing, why the 2026 market looks different from 2021, and how the sponsor’s identity should shape your negotiation at the table.

---

What does a PE sponsor actually mean for your veterinary practice sale in 2026?

A PE sponsor — short for private equity sponsor — is the investment firm that controls the buyer you’re talking to. Think of it this way: NVA is owned by JAB Holding Company.

Thrive Pet Healthcare (formerly Pathway Vet Alliance) is backed by TSG Consumer Partners. PetVet Care Centers has KKR as its current primary backer.

Mission Pet Health, the combined entity formed from Southern Veterinary Partners and Mission Veterinary Partners, operates with Shore Capital as its anchor sponsor and Silver Lake Partners as a major additional backer following the December 2024 merger. The buyer sitting across from you isn’t a freestanding company — it’s a portfolio company inside a PE fund, and that fund has rules.

Every private equity fund is built on the same essential architecture: a general partner (the PE firm) raises capital from institutional investors called limited partners — university endowments, pension funds, insurance companies — with a defined investment period and a target exit window. The hold period is the length of time a fund actually owns a portfolio company before selling it.

Historically that has run 3 to 7 years for veterinary consolidators. The sponsor’s job is to grow the platform during that window and then exit at a return that satisfies the limited partners who put up the capital.

That fund clock is what makes the PE buyer’s sponsor identity meaningful for you. Your rollover equity will be illiquid until that exit happens.

And when the exit happens — and how — is largely the sponsor’s decision to make.

---

How does the private equity veterinary practice buyer hold period affect what you actually receive?

The clearest way to see this is to think about what a typical deal structure looks like in 2026, and then map the sponsor’s hold period onto it.

When a PE-backed buyer acquires a practice, the total consideration typically includes cash at close plus some form of rollover equity — a portion of the sale price that stays invested in the platform rather than coming to you as cash. PE-backed buyers commonly ask sellers to roll somewhere in the range of 10 to 40 percent of total consideration back into the platform.

The rolled amount is generally tax-deferred at closing, which is a meaningful structural advantage. We cover the full mechanics in the earnout and rollover equity guide.

The cash portion goes into your account on closing day. The rollover equity stays in the platform.

That equity has no market — there’s no stock exchange, no liquidity mechanism. It converts to cash only when the platform exits.

That’s the sponsor’s call.

So here’s the logic the sponsor’s fund age creates:

A buyer whose sponsor just closed a new fund two years ago may be in acquisition mode for another 3 to 4 years before pivoting to exit preparation. Add a hold period, and you’re looking at a potential liquidity event 7 to 10 years out from your closing date.

A buyer whose sponsor is already 4 or 5 years into the fund is closer to the exit window — and your liquidity event could come in 2 to 3 years if the market cooperates.

Neither scenario is automatically better. A longer hold gives the platform more time to grow before it exits, which could increase the value of your rolled equity.

A shorter hold means faster liquidity. The point is simply this: the fund’s vintage shapes your personal timeline, and that timeline belongs in your negotiation, not your post-closing reading.

---

The 2026 exit environment: why so many platforms are still waiting

The veterinary PE landscape going into 2026 is carrying the weight of a multi-year exit freeze.

From 2017 to 2022, private equity firms invested roughly $45 billion in US veterinary sector deals, per Octus’s private credit research. Many of those funds closed platforms at aggressive multiples during the near-zero interest rate years.

Then the Federal Reserve raised rates from near 0 to 5 percent by mid-2023 — and suddenly the math that justified billion-dollar platform valuations no longer worked for potential buyers trying to finance a new acquisition.

The recapitalization market for veterinary consolidators froze. The only major recapitalization event between mid-2022 and mid-2025 was the SVP and MVP merger that created Mission Pet Health, announced in September 2024 and formally completed in December 2024, with the combined brand publicly launched in July 2025 per the Mission Pet Health press release.

That $8.6-billion-scale transaction remained an outlier as interest rates stayed elevated and deal financing tightened.

Capstone Partners‘ April 2026 Pet Sector M&A Update frames the pressure in a single number: financial sponsors formed 66 veterinary platforms between 2019 and 2022 that have since reached or moved past their prime harvest years. LP demand for distributions — the institutional investors who funded those sponsors are waiting for cash back — is pushing sponsors toward exits in 2026 and 2027 even in a still-uncertain rate environment.

The result: 18 announced or completed pet sector M&A transactions year-to-date through Capstone’s April 2026 update, up from 8 in the prior-year period. The exit environment is improving.

But it is not uniform, and not every platform is in the same position.

This matters to you because a platform under LP exit pressure is a different negotiating environment than a platform still in build mode. The first is trying to position for a near-term exit at a favorable number; you’re a piece of a sale story they’re constructing.

The second is in acquisition mode; they want your practice as a component of growth, and your rolled equity will sit for a while.

---

What the sponsor’s identity tells you about deal structure in 2026

Not every sponsor’s approach is identical. The publicly available information about major veterinary consolidators‘ sponsors — from their own press releases, portfolio pages, and industry press — reveals some meaningful patterns worth understanding.

JAB Holding Company / NVA. JAB acquired National Veterinary Associates in 2019 for approximately $5.3 billion. Unlike a traditional PE fund with a fixed investment horizon, JAB is a private family holding company — not a time-pressured fund.

In 2023, JAB announced it would split NVA into two separately managed pet hospital businesses, signaling active thinking about eventual exit paths, including the possibility of a public offering for one or both entities. The lack of a hard fund deadline gives JAB more patience than a traditional sponsor — which means any rollover equity in an NVA-affiliated transaction could be tied up longer than a typical fund-cycle scenario.

As AVMA’s reporting on the NVA split noted, JAB retained flexibility to take either entity public or sell separately. NVA does not publish standard price terms; any offer from NVA should be evaluated through a competitive process to understand its full range.

Shore Capital Partners / Mission Pet Health. Shore Capital is the anchor sponsor on both the legacy SVP and MVP entities that merged into Mission Pet Health. The SVP-MVP transaction, at roughly $8.6 billion in total deal scale, also brought in Silver Lake Partners as a new major investor — meaning Mission Pet Health enters 2025 and 2026 with fresh capital behind it and is in active deployment mode.

The recapitalization that created Mission Pet Health is itself an example of what a recap looks like in practice: a PE sponsor merging two portfolio companies, bringing in new capital, and resetting the exit clock.

TSG Consumer Partners / Thrive Pet Healthcare. Thrive (formerly Pathway Vet Alliance) completed a distressed debt exchange in March 2025, extending all maturities to 2028 and drawing in $350 million in new liquidity, per the Latham & Watkins press release advising on the transaction. That means Thrive enters 2026 with refinanced debt but no near-term exit on the horizon.

For sellers considering a Thrive transaction, the platform’s capital structure is a relevant factor — the sponsor is managing a complex debt situation, not positioning for an imminent exit.

KKR / PetVet Care Centers. PetVet, backed by KKR with additional capital from Blue Owl and CVC, operates as one of the largest general-practice veterinary consolidators with 420-plus locations. KKR’s involvement brings deep institutional resources and a long track record in healthcare sector consolidation.

PetVet has not publicly announced any near-term exit.

The takeaway across all of these isn’t to rank them or draw unfavorable comparisons. It’s to make the point that the sponsor behind a buyer is a publicly researchable fact, and it shapes the deal you’re actually doing.

Sellers who know this information going in are simply better positioned.

---

The second bite: what it can be worth, and what can go wrong

The second bite of the apple is the reason many vets accept rollover equity rather than demanding all cash at close. And under the right circumstances, it’s a legitimate wealth-building tool.

Here’s how it works. When you roll equity into the platform at closing, you become a minority owner of a growing company.

If the platform increases its earnings, and if the sponsor exits at a multiple that reflects that growth, your rolled equity is worth more at the exit than it was at your original close. In a healthy scenario — platform grows EBITDA, market conditions support a strong exit multiple — the second check can be as large as or larger than the first.

The math that makes this compelling: suppose a platform was valued at a given EBITDA multiple at the time of your sale. You rolled 20 percent of your proceeds back in.

If the platform grows its EBITDA and exits at a comparable or higher multiple — typical in a secondary buyout where the platform has scaled — your 20 percent stake is worth more in absolute terms even if the multiple stayed flat. Scale on the same multiple generates more dollars.

And multiples at the platform level, per Octus’s 2025 research on private-credit exposure to veterinary rollups, can run well above practice-level multiples when a large consolidated entity goes to market.

But the risks are equally real, and experienced sellers think about them before signing.

The lockup risk. Rollover equity is illiquid. You cannot force a PE firm to buy you out.

Per legal analysis from Mahan Law’s rollover equity attorney practice, veterinary sellers who rolled equity at the original sale cannot convert that equity to cash until the holding company cooperates — meaning until there’s a recapitalization or sale event. If the sponsor’s exit takes a decade, your equity waits a decade.

The open-ended lockup is the single most overlooked risk in PE deals.

The platform performance risk. Second-bite upside assumes the platform is worth more at exit than at entry. That’s not guaranteed.

Octus’s private-credit research found BDCs holding $3.1 billion in principal lent to veterinary companies as of the third quarter of 2025, with several large platforms experiencing operating pressure from labor inflation, staffing shortages, and declining patient visit volumes. Ares reduced the fair value of its subordinated loans to AmeriVet to 83 percent of par in Q3 2025, per the same Octus research.

Platforms that take on heavy debt to fund acquisitions carry more risk than a clean balance sheet. Your rolled equity participates in that risk.

The dilution risk. PE sponsors can issue new equity — for new acquisitions, for management incentives, for refinancing. Without anti-dilution provisions, your percentage ownership can shrink between your closing date and the eventual exit, reducing your second-bite proceeds.

The professionals who represent sellers in PE transactions negotiate around all three of these risks. Define the lockup window.

Negotiate a put right or a co-sale right at the sponsor’s exit. Understand the platform’s debt structure before you roll.

These are not exotic asks — they’re standard points for anyone representing your interests in a PE deal.

---

How the competitive process changes the sponsor conversation

Here’s the insight that years of running processes has cemented for me. A single direct offer from one PE-backed buyer — on the buyer’s timeline, their terms, their rollover ask — gives you exactly one reference point.

You don’t know if the rollover percentage is standard or aggressive. You don’t know how the sponsor compares to the one behind the next buyer’s offer.

You don’t know if the platform’s debt load is typical or on the high end.

A properly structured competitive process changes all of that. When multiple qualified buyers are in the room — each with a different sponsor, different fund vintage, different exit horizon — you see the full range.

Not just on headline price, but on cash-versus-rollover split, lockup terms, governance rights, and management expectations post-close. The differences between sponsors become visible when you’re comparing their offers side by side rather than evaluating one in isolation.

That’s precisely what the Elite Selling System is designed to surface. We hand-select and vet every buyer who gets to see your practice, the way a doorman with a velvet rope admits only the right people.

Within that vetted pool, we run a private competitive bidding window. The price signal that comes back from 6 to 8 competing PE-backed buyers is almost always higher than any direct offer.

More importantly for this article, the deal structure — including the rollover terms — is far more negotiable when multiple buyers are competing for the same asset.

We cover the valuation mechanics in depth on the who to sell your veterinary practice to page and in the buy-sell process guide. What I’ll say here is specific to the PE sponsor question: the competitive process is the only mechanism that gives you real data on how different sponsors are pricing your practice and structuring the rollover at the same moment.

---

A comparison table: what different sponsor types mean for your sale

The table below summarizes how key attributes of a buyer’s sponsor translate into deal implications for the seller. This is not a ranking — each structure has trade-offs — it’s a framework for reading what you’re looking at.

Sponsor type	Typical hold period	Exit path	Rollover liquidity timing	Key seller consideration
Traditional PE fund (closed-end)	4–7 years	Secondary buyout, IPO, or strategic sale	Tied to fund’s exit event	Ask about fund vintage and remaining life
Family holding company (e.g., JAB)	No fixed deadline	Strategic transaction at sponsor’s discretion	Potentially longer than a traditional fund	Negotiate explicit liquidity provisions
Sponsor just post-recap (fresh capital)	4–7 years from recap date	Next secondary buyout or IPO	Locked through new fund cycle	Active acquisition mode; timeline resets
Sponsor near end of fund life	1–3 years to exit	Urgent sale or secondary	Faster potential liquidity	Favorable timing for rollover sellers
Platform with debt stress	Uncertain	Depends on debt resolution	Unpredictable	Understand debt load before rolling equity

One note on that last row: a platform with a complex debt structure isn’t automatically a bad deal. Debt is how PE builds leverage, and leverage amplifies returns when things go well.

The point is transparency — know what you’re rolling equity into before you sign.

---

What to do before you accept a PE-backed offer in 2026

There’s a version of this conversation that sellers have after closing, usually over dinner in a different context, where they realize they didn’t ask enough questions about the sponsor. I’d rather have it with you before.

Before you accept any PE-backed offer — or before you enter a sale process — these are the questions worth getting answered:

Who is the sponsor, and how old is the fund? A 2019 fund is very different from a 2023 fund. Ask for the fund’s vintage.

If the buyer won’t answer, look it up — most PE firms list their funds on their websites and through EDGAR.

What is the rollover structure, specifically? What percentage is expected? Is it negotiable?

What governance rights attach to that equity? Is there an anti-dilution provision?

What triggers liquidity for my rolled equity? An open-ended lockup with no defined event is a risk. You want a defined milestone — a 5-year put right, a co-sale right at the sponsor’s exit, or another mechanism — that gives you a path to cash that doesn’t depend entirely on the sponsor’s timing.

What is the platform’s debt load? Octus’s research is available to anyone with a subscription, and your legal and financial advisors should be reading it. Understand what’s on the balance sheet before you’re part of it.

How does your practice fit into their growth story? A platform in active acquisition mode is different from one winding down. The answer shapes your post-close operating life, not just your financial outcome.

These are not hostile questions. Every sophisticated buyer’s team expects them.

If you bring professional representation to the table, your advisor will ask them before a single term is agreed.

---

What comes next

If you’re evaluating an offer from a PE-backed buyer, or if you’re thinking about whether to start a sale process, the sponsor question is one of a dozen things that need to be resolved before you decide. The veterinary practice consolidators overview maps the full buyer landscape.

The practice valuation guide anchors you on what your practice is worth before any buyer conversation starts.

What I’ll tell you from the work we do: the practice owners who get the best outcomes from PE-backed transactions are the ones who understand the fund mechanics before they agree to anything. They know what they’re rolling into.

They’ve negotiated the lockup. And they know that a single direct offer from one sponsor isn’t the ceiling — it’s the floor.

The gap between that floor and what a competitive process delivers is what our work exists to close.

Get a Free Practice Value Estimate →

If you’d like a sense of what your practice is worth before a PE buyer’s term sheet arrives, we’re happy to walk through it. The conversation starts with your financials and your timeline.

There’s no obligation on your side — and the estimate we give you is grounded in the actual deal data from the competitive processes we’ve run, not a model built from public averages.

Our engagement model is success-based. We’re not paid until a deal closes, and we’re only paid out of the value we create above what you would have cleared on your own.

That alignment is the entire point.

---

Frequently asked questions

What does a PE sponsor’s hold period mean for a veterinary practice sale in 2026?

A PE sponsor’s hold period tells you how long the firm plans to own the platform before exiting — typically 3 to 7 years — and by extension, how long your rollover equity will be illiquid. If you sell to a buyer whose sponsor is already 5 or 6 years into its fund, an exit may come within 2 to 3 years.

Sell to a sponsor that just closed a new fund and your equity could be tied up for 7 or more years. The sponsor’s vintage and fund age matter as much as the headline price.

What is a private equity hold period in veterinary practice acquisitions?

A hold period is the length of time a private equity firm owns a portfolio company before exiting through a sale, merger, or public offering. In veterinary practice consolidation, hold periods have historically run 3 to 7 years.

The post-2022 interest rate environment pushed many sponsors beyond that range, with holding backlogs for buyout funds aged 7 years or older reaching roughly $863 billion globally by mid-2025, per PwC private markets data.

What is the second bite of the apple in a veterinary practice sale?

The second bite of the apple is a second liquidity event for a seller who kept equity in the PE-backed platform at closing. When the platform is recapitalized or sold — typically 3 to 7 years after the original acquisition — the seller’s rolled equity converts to cash at the new, higher platform valuation.

If the platform’s earnings grew and the exit multiple held, that second check can exceed the first in some cases.

How does a private equity recapitalization affect veterinary practice owners in 2026?

A recapitalization is the most common path to a second payout for practice owners who rolled equity. The sponsor sells the platform — or a majority stake — to a new buyer, often another PE firm, at a higher valuation than the original purchase.

Owners who hold rollover equity receive their share of the proceeds at that point. The SVP and MVP merger that created Mission Pet Health in late 2024 and launched publicly in July 2025 is the most recent large-scale example of a recapitalization event in the veterinary sector.

How much rollover equity do PE buyers typically ask for in veterinary practice sales?

PE-backed buyers commonly ask sellers to roll 10 to 40 percent of their total deal consideration back into the platform as equity. The rolled amount is generally tax-deferred at the time of closing.

The specific rollover expectation on any given offer is negotiated case by case and depends on the buyer’s capital structure, deal size, and how much the seller wants to participate in future upside.

Why are PE platforms having trouble exiting veterinary practices in 2025 and 2026?

The Federal Reserve’s rate cycle pushed PE borrowing costs sharply higher from 2022 onward, compressing the valuations acquirers could justify for large platforms. The recapitalization market for veterinary consolidators essentially froze from mid-2022 through mid-2025.

Capstone Partners‘ April 2026 Pet Sector M&A Update reports that financial sponsors formed 66 platforms between 2019 and 2022 that have reached or moved beyond prime harvest years, creating growing LP pressure for distributions.

What is the difference between a strategic buyer and a PE-backed buyer for a veterinary practice?

A strategic buyer — the only major example in veterinary care is Mars Veterinary Health, which owns VCA, Banfield, and BluePearl — is a permanent, family-owned owner with no fund lifecycle forcing an exit. A PE-backed buyer operates on a fund clock: the firm raised capital from institutional investors, must deploy it, grow value, and ultimately exit to return cash.

That fund clock is what creates the hold period, and the hold period is what determines when your rolled equity can convert to cash.

What should veterinary practice owners know about rollover equity lockup before signing?

Rollover equity in a PE-backed platform is illiquid until the platform exits. You cannot force the PE firm to buy you out.

Your equity converts to cash only when the sponsor recapitalizes or sells — and that could take 3 to 10 years depending on market conditions. Before signing, negotiate a defined liquidity window tied to specific milestones: the 5-year mark, a sponsor-led recapitalization event, or another trigger.

An open-ended lockup with no defined exit mechanism is a real risk.

---

Sources

Industry M&A research and valuation data

1. Capstone Partners. “Pet Sector M&A Update — April 2026.” capstonepartners.com
2. Octus. “Private-Credit Exposure to Veterinary Rollups Shows Growing Dispersion; VSOs Under Increasing Pressure.” 2025. octus.com
3. PwC. “Capital Considerations: Private Equity Exit Drought.” pwc.com
4. Dechert LLP. “Dechert Sees Strong M&A and Private Equity Activity in Early 2026.” dechert.com

Legal and regulatory analysis

5. Holland & Knight. “2025 Private Equity Year in Review.” March 2026. hklaw.com
6. Holland & Knight. “Up Next: Vet Clinic Acquisitions Targeted for Review and Approval in New York.” September 2025. hklaw.com
7. Mahan Law. “Rollover Equity Attorney for Veterinarians.” mahanlaw.com

Public company disclosures and PE filings

8. Mission Pet Health. “Southern Veterinary Partners and Mission Veterinary Partners Join Together as Mission Pet Health.” Press release, July 21, 2025. missionpethealth.com
9. AVMA. “NVA splits into two businesses, may go public in next few years.” avma.org
10. Latham & Watkins. “Latham & Watkins Advises on Thrive Pet Healthcare’s US$350+ Million Financing.” March 2025. lw.com
11. Harvest Partners. “VetCor Closes Recapitalization.” harvestpartners.com
12. AEA Investors. “AEA Acquires AmeriVet Partners Management, Inc.” aeainvestors.com

Veterinary practice and private equity context

13. AAHA. “Corporate Consolidation and the Rise of Private Equity.” Trends Magazine. aaha.org
14. Axios. “Private Equity Firms Find COVID-Fueled Veterinarian Deals Hard to Exit.” February 2026. axios.com